
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































The kit is developed for quantitative detection of natural and recombinant human IL-2 in serum, plasma and cell culture supernatants.
It is for research use only.

| Assay Type | Sandwich-ELISA |
| Analyte | IL-2 |
| Format | 96-wells plate breakable into 12 x 8 wells strips |
| Reactivity | Human |
| Sensitivity | 5.0 pg/mL |
| Assay Time | 1.75 hr |
| Sample volume | 50 μL |
| Range | 6.25 pg/mL-800 pg/mL |
| Sample Type | Cell Culture Supernatants, Plasma, Serum. |
| NIBSC Code | 86/500 |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.

For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of IL-2 is less than 5.0pg/mL.
Serum Sample: two hundred and forty samples from healthy volunteers were tested for the presence of human IL-2 concentration in the assay. One hundred and eighty-four samples were detectable. No medical histories were available for the donors used in this study.

Six types of materials were tested to observe if there were matrix effect (interference). If the concentration of bilirubin (simulated jaundice) is less than 20 mg/dL, the concentration of hemoglobin (simulated hemolysis) is less than 3500 mg/dL, the concentration of triglyceride (simulated lipid blood) is less than 2.0 g/L, Heparin concentration is less than 40U/mL, EDTA concentration is less than 4 mg/mL, and Sodium Citrate Plasma concentration is less than 40 mg/mL, testing results will not be affected.

High concentrations of human IL-2 serum samples were diluted with 1:2, 1:4, and 1:8 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of IL-2 was 97.38%.

Ten replicates of each of three samples containing different IL-2 concentrations were tested in one assay. Acceptable criteria: CV<10%.

Three samples containing different concentrations of IL-2 were tested in the independent assays. Acceptable criteria: CV<15%.

IL-2 was spiked into five human serum samples, and then analyzed. The average recovery of IL-2 for serum samples is 97.58%.

| ID | Components | Size |
| CRB008-C01 | Pre-coated Anti-IL-2 Antibody Microplate | 1 plate |
| CRB008-C02 | Human IL-2 Standard | 25 μg×2 |
| CRB008-C03 | Biotin-Anti-IL-2 Antibody Con. Solution | 100 μL |
| CRB008-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
| CRB008-C05 | Streptavidin-HRP Con. Solution | 500 μL |
| CRB008-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
| CRB008-C07 | 20×Washing Buffer | 50 mL |
| CRB008-C08 | 1×Dilution Buffer | 15 mL×2 |
| CRB008-C09 | Substrate Solution | 12 mL |
| CRB008-C10 | Stop Solution | 6 mL |
Price(USD) : $498.00
Price(USD) :
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| SHR-1916 | SHR-1916 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours | Details |
| STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Skin Appendage; Basal Cell Nevus Syndrome; Keratoacanthoma; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
| ITI-1000 | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| NNC-0361-0041 | NNC0361-0041; NNC-0361-0041 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1 | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Solid tumours | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
| AU-007 | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| PM-1016 | PM1016; TILT-123 | Phase 2 Clinical | Tilt Biotherapeutics Ltd | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| EQ101 | EQ101 | Phase 2 Clinical | Equillium Inc | Alopecia; Alopecia Areata | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Carcinoma, Basal Cell; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| attIL2-T cell therapy | Phase 1 Clinical | MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
| Saltikva | Phase 2 Clinical | Salspera LLC | Pancreatic Neoplasms | Details | |
| AVB-001 | AVB-001 | Phase 2 Clinical | Avenge Bio Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
This web search service is supported by Google Inc.




